Pharma stock jumps 15% after its net profit increases by 35% QoQPharma stock jumps 15% after its net profit increases by 35% QoQ

Introduction:

Pharma stock reported a 35% QoQ rise in Q3 FY25 net profit, reflecting strong financial growth. Revenue increased, while profit before tax surged. The company also declared an interim dividend, reinforcing its market position and expanding its pharmaceutical manufacturing capabilities.

Share Price movement of Aarti Pharmalabs:

On February 6, 2025, Aarti Pharmalabs Ltd opened at ₹734.00, up 15.36% from its previous close of ₹636.30. The stock reached a high of ₹747.00 and a low of ₹662.40. It last traded at ₹672.60, a 5.70% increase, with a market cap of ₹6,095.51 crore.

Aarti Pharmalabs Q3 Results:

Aarti Pharmalabs’ Q3 FY25 net profit surged 40.2% YoY and 35% QoQ to ₹73.99 crore, driving a 14.32% stock jump to ₹728.85. Revenue from operations grew 19.9% to ₹537.78 crore. Profit before tax rose 36.3% YoY to ₹100.63 crore, reflecting strong financial performance.  

Total expenses increased 17.5% YoY to ₹442.18 crore, with material costs up 21.5% and employee expenses rising 15.1%. Finance costs surged 122.5% YoY to ₹9.97 crore. On a nine-month basis, net profit climbed 21.4% to ₹184.06 crore, while revenue increased 15.2% YoY to ₹1,551.30 crore.  

The company declared an interim dividend of ₹2.5 per share, with a record date of February 14, 2025. Aarti Pharmalabs specializes in manufacturing APIs, pharmaceutical intermediates, NCEs, and xanthine derivatives, strengthening its global pharmaceutical presence with continued business growth.

Also Read:  Logistics stock hits 20% upper circuit after reporting 334% YoY increase in net profits

Recent news About Aarti Pharmalabs :

Aarti Pharmalabs has resumed manufacturing activities at its Vapi plant as of January 18, 2025, after a temporary closure earlier in the month.

Ace investor holding of  Aarti Pharmalabs:

Nishant Pradip Shah holds a 1.10% stake in Aarti Pharmalabs Ltd., owning 9.97 lakh shares worth ₹66.7 crore. He also has a 1.21% stake in Aarti Surfactants Ltd. with 1.02 lakh shares valued at ₹6.2 crore, showcasing strategic investments in specialty chemicals.

Stock performance of Aarti Pharmalabs for Period of 1 week, 6 months and 1 year:

Aarti Pharmalabs’ stock gained 8.42% over the past week, reflecting strong short-term momentum. Over six months, it rose 6.94%, showing steady growth. Over the past year, the stock delivered a 14.1% return, indicating consistent performance and investor confidence in its long-term potential.

Also Read: Mukul Agrawal stock falls 5% after its net profits decline by 35% YoY 

Shareholding pattern of Aarti Pharmalabs:

All values in %	Dec-24	Sep-24	Jun-24
Promoters	44.66	46.1	46.46
FII	8.64	7.38	7.07
DII	10.36	11.35	11.47
Retail & others	36.34	35.18	35.01

About Aarti Pharmalabs:

Aarti Pharmalabs is a leading manufacturer of active pharmaceutical ingredients (APIs), pharmaceutical intermediates, and specialty chemicals. The company focuses on innovation, global expansion, and sustainable manufacturing, catering to diverse industries while strengthening its position in the pharmaceutical and chemical sectors.

Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time The securities quoted are exemplary and are not recommendatory.